{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:47:27Z","timestamp":1765806447319,"version":"build-2065373602"},"reference-count":61,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,12,8]],"date-time":"2004-12-08T00:00:00Z","timestamp":1102464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2005,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The objective of this study was to estimate the ideal proportion of new patients with leukemia and myeloma who should receive radiotherapy at some time during the course of their illness based on the best evidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Available evidence of the efficacy of radiotherapy in most clinical situations for leukemia and myeloma was identified through extensive literature reviews and treatment guideline searches. Epidemiologic data concerning the distribution of types, disease stages, and other factors that influence the use of radiotherapy were identified. Decision trees were constructed to merge the evidence\u2010based recommendations with the epidemiological data to calculate the optimal proportion of patients who should receive radiotherapy according to the best available evidence. Actual radiotherapy utilization rates also were identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The proportion of patients diagnosed with myeloma in Australia who should receive radiotherapy based on the evidence was 38%. There was wide variation in the proportion of patients who actually received radiotherapy for myeloma from 24% up to 55%. The recommended proportion of patients diagnosed with myeloma in Australia who, according to the best available evidence, should receive at least a single course of radiotherapy was 38%. The proportion of patients diagnosed in Australia with leukemia who should receive radiotherapy at some point in their management, according to the best available evidence, was calculated at 4%, which corresponded with actual practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Further research will be required to determine why more patients who are diagnosed with myeloma are not treated with radiotherapy. Cancer 2005. \u00a9 2004 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.20755","type":"journal-article","created":{"date-parts":[[2005,1,5]],"date-time":"2005-01-05T13:26:42Z","timestamp":1104931602000},"page":"393-401","source":"Crossref","is-referenced-by-count":29,"title":["Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence"],"prefix":"10.1002","volume":"103","author":[{"given":"Carolyn","family":"Featherstone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoff","family":"Delaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susannah","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Barton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,1,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1673.2000.00833.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1673.1995.tb00264.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841869109092417"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(94)90096-5"},{"key":"e_1_2_6_6_2","unstructured":"RobertsonG. An aid to planning cancer services in Scotland in the next decade. Prospects for radiation oncology [monograph on line] Available from URL:www.scotland.gov.uk[accessed July2004]."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/02841860310011131"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11740"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)00984-7"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20092"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20443"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20444"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20445"},{"key":"e_1_2_6_14_2","unstructured":"National Cancer Institute. CancerNet PDQ cancer information summaries: treatment of acute lymphoblastic leukaemia in children. Available from URL:www.nci.nih.gov[accessed July2004]."},{"key":"e_1_2_6_15_2","unstructured":"National Cancer Institute. CancerNet PDQ cancer information summaries: treatment of acute lymphoblastic leukaemia in adults. Available from URL:www.nci.nih.gov[accessed July2004]."},{"key":"e_1_2_6_16_2","unstructured":"National Cancer Institute. CancerNet PDQ cancer information summaries: treatment of acute myeloid leukaemia in adults. Available from URL:www.nci.nih.gov[accessed July2004]."},{"key":"e_1_2_6_17_2","unstructured":"National Cancer Institute. CancerNet PDQ cancer information summaries: treatment of acute myeloid leukaemia in children. Available from URL:www.nci.nih.gov[accessed July2004]."},{"key":"e_1_2_6_18_2","unstructured":"National Cancer Institute. CancerNet PDQ cancer information summaries: treatment of chronic lymphocytic leukaemia. Available from URL:www.nci.nih.gov[accessed July2004]."},{"key":"e_1_2_6_19_2","unstructured":"National Cancer Institute. CancerNet PDQ cancer information summaries: treatment of chronic myelogenous leukaemia. Available from URL:www.nci.nih.gov[accessed July2004]."},{"key":"e_1_2_6_20_2","unstructured":"National Cancer Institute. Cancernet PDQ guidelines on multiple myeloma. Available from URL:www.nci.nih.gov[accessed July2004]."},{"key":"e_1_2_6_21_2","unstructured":"National Comprehensive Cancer Network. Guidelines on chronic myelogenous leukaemia. Available from URL:www.nccn.org(accessed September Day 2002)."},{"key":"e_1_2_6_22_2","unstructured":"National Comprehensive Cancer Network. Guidelines on acute myeloid leukaemia. Available from URL:www.nccn.org[accessed July2004]."},{"key":"e_1_2_6_23_2","unstructured":"National Comprehensive Cancer Network. Guidelines on multiple myeloma. Available from URL:www.nccn.org[accessed July2004]."},{"key":"e_1_2_6_24_2","unstructured":"British Committee for Standards in Haematology. Guidelines for non\u2010Hodgkin's lymphoma [draft monograph on line] 2001. Available from URL:www.bcshguidelines.com[accessed July 2004]."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03206.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012460506219"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012448104402"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012456405311"},{"volume-title":"Guide to the development, implementation and evaluation of clinical practice guidelines. Appendix B","year":"1998","author":"National Health and Medical Research Council","key":"e_1_2_6_29_2"},{"volume-title":"Basic Markov modeling","year":"2001","author":"Treeage Software Inc.","key":"e_1_2_6_30_2"},{"key":"e_1_2_6_31_2","unstructured":"Northern and Yorkshire Cancer Registry. Cancer registry and information service within the Leeds Teaching Hospitals NHS Trust 1999. Quickdata on line. Available from URL:http:\/\/www.nycris.org.uk[accessed July 2004]."},{"key":"e_1_2_6_32_2","series-title":"Cancer Series","volume-title":"Epidemiology of cancer in South Australia","author":"South Australia Cancer Registry","year":"2000"},{"volume-title":"SEER cancer incidence data base, 1973\u20131997","year":"2000","author":"U.S. Department of Health and Human Services","key":"e_1_2_6_33_2"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340802"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.593"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02851.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00567.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0004-8461.2003.01144.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-6196(25)00115-6","article-title":"Multiple Myeloma","volume":"50","author":"Kyle RA","year":"1975","journal-title":"Mayo Clin Proc."},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)00984-7"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3569"},{"volume-title":"Cancer incidence data: cancer age\u2010standardised database, 1997","year":"2001","author":"Australian Institute of Health and Welfare (AIHW)","key":"e_1_2_6_42_2"},{"key":"e_1_2_6_43_2","unstructured":"New South Wales Cancer Registry. Epidemiology of cancer in New South Wales [monograph on line]. Available from URL:http:\/\/www.nswcc.org[accessed July2004]."},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90164-7"},{"key":"e_1_2_6_45_2","first-page":"3310","article-title":"Improved outcome in acute lymphoblastic leukaemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL\u2010BMF\u201090","volume":"95","author":"Schrappe M","year":"2000","journal-title":"Blood."},{"key":"e_1_2_6_46_2","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1182\/blood.V96.7.2412","article-title":"Bone marrow transplantation versus chemotherapy in the treatment of very high\u2010risk childhood acute lymphoblastic leukaemia in first remission: results from Medical Research Council UKALL X and XI","volume":"96","author":"Wheeler KA","year":"2000","journal-title":"Blood."},{"key":"e_1_2_6_47_2","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V84.9.3122.3122","article-title":"Chemotherapy in 998 unselected childhood acute lymphoblastic leukaemia patients. Results and conclusions of the multicenter trial ALL\u2010BFM 86","volume":"84","author":"Reiter A","year":"1994","journal-title":"Blood."},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310283291801"},{"key":"e_1_2_6_50_2","first-page":"1226","article-title":"Intensive treatment of children with acute lymphoblastic leukaemia according to ALL\u2010BFM\u201086 without cranial radiotherapy: results of Dutch Childhood Leukaemia Study Group protocol ALL\u20107 (1988\u20131991)","volume":"94","author":"Kamps WA","year":"1994","journal-title":"Blood."},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311902"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2002.1.162"},{"key":"e_1_2_6_53_2","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five\u2010drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukaemia: Cancer and Leukaemia Group B study 8811","author":"Larson R","year":"1995","journal-title":"Blood."},{"key":"e_1_2_6_54_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood.V73.1.57.57","article-title":"Treatment of acute lymphoblastic leukaemia in adults with intensive induction, consolidation, and maintenance chemotherapy","volume":"73","author":"Hussein KK","year":"1989","journal-title":"Blood."},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392301"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2322"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)09214-3"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90120-E"},{"key":"e_1_2_6_59_2","first-page":"7","article-title":"Impact on survival of high\u2010dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population\u2010based study","volume":"95","author":"Lenhoff S","year":"2000","journal-title":"Blood."},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_6_61_2","unstructured":"DjulbegovicB WheatleyK RossJ et al. Bisphophonates in multiple myeloma. Cochrane Library 2003. Available from URL:http:\/\/www.cechrone.org[accessed July 2004]."},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20754"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20755","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:14:11Z","timestamp":1760289251000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20755"}},"subtitle":["Part II\u2014Leukemia and myeloma"],"short-title":[],"issued":{"date-parts":[[2005,1,5]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,1,15]]}},"alternative-id":["10.1002\/cncr.20755"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20755","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2005,1,5]]}}}